

We Claim:

1. Duloxetine, for use in the treatment of a disorder in a patient having a disorder, wherein the disorder is:

5 inflammatory bowel disease (IBD),
functional bowel disorders (FBD),
dyspepsia,
ileitis,
ischemic bowel disease,
10 irritable bowel syndrome,
gastroesophageal reflux, and
diarrhea.

2. A use of Claim 1 wherein the disorder is irritable bowel syndrome.

15

3. The use of duloxetine for the manufacture of a medicament for treating a disorder in a patient wherein the disorder is as claimed in any one of claims 1 or 2.

4. A pharmaceutical composition for treating a disorder in a patient,
20 comprising duloxetine as the active ingredient, associated with one or more
pharmaceutically acceptable carriers, wherein the disorder is as claimed in any one of
Claims 1 or 2.